
Please try another search
By Dhirendra Tripathi
Investing.com – Applied Therapeutics stock (NASDAQ:APLT) sank 25% in Monday’s pre-market trading after receiving bad news from the FDA for the company’s lead drug candidate.
The company was earlier expecting an accelerated approval for the drug AT-007, which aims to treat galactosemia, a rare genetic metabolic disease, from the Food and Drug Administration, but the regulator has now indicated that clinical outcomes data will likely be required for it, according to a company release. The company has thus decided to hold on submitting a new drug application for AT-007 for treatment of galactosemia pending additional discussions with the FDA.
The first assessment of the clinical outcome will be completed in the first quarter of 2022, and then every 6 months thereafter until the study reaches statistical significance, the release said.
The company is developing AT-007 for treatment of galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize the simple sugar galactose. When not metabolized properly, galactose is converted to the toxic metabolite, galactitol, which causes neurological complications, including deficiencies in speech, cognition, behavior and motor skills.
AT-007 is currently being studied in a phase-3 clinical outcomes trial (ACTION-Galactosemia Kids) in 2-17-year-olds suffering from galactosemia. There are approximately 3,000 patients with galactosemia in the US and 80 new births per year.
(Reuters) - A U.S. appeals court has ruled that the federal government may transfer thousands of acres in Arizona to Rio Tinto (NYSE:RIO) Plc for a copper mine in a land swap...
By Pamela Barbaglia and Anirban Sen LONDON/NEW YORK (Reuters) - Global dealmaking is entering an arid season as raging inflation and a stock market rout curb the appetite of many...
SHANGHAI (Reuters) - China's securities regulator proposed rules to regulate private pension investment via mutual funds, setting the criteria for qualified products and sales...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.